Overview
64x Bio is an innovative biotechnology company dedicated to advancing the manufacturing capabilities for cell and gene therapies. Through their proprietary platform technologies, the company focuses on integrating high throughput genome engineering and screening technologies with computational tools to expedite the discovery and optimization of mammalian cell lines. This aids in the development of next-generation therapeutics, thereby enhancing the landscape of cell and gene therapy.
Mission and Technology
The mission of 64x Bio is to revolutionize the future of cell and gene therapy by creating innovative engineering platforms that enhance the speed and accessibility of therapeutic solutions. Their technologies are meticulously designed to scale and streamline the development and manufacturing processes involved in gene therapies. A key technology, their VectorSelect™ platform, is essential in the design and improvement of cell lines for a wide range of gene therapies.
Leadership Team
- Lexi Rovner - Co-founder and Chief Executive Officer
Lexi Rovner leads 64x Bio with a strategic vision focused on integrating their advanced technologies into the biopharmaceutical industry. With a background as a postdoctoral fellow under George Church at Harvard Medical School, she contributes a strong scientific and operational foundation to the company.
- David Thompson - Co-founder
Brings scientific leadership from his time as a scientist at Wyss Institute, contributing significantly to 64x Bio's research directions.
- Farhad Paylakhi - Co-founder and Vice President of Research and Development
Heads the R&D efforts focusing on molecular genetics, which are vital to the company’s gene therapy innovations.
- George Church - Co-founder
A respected geneticist whose pioneering insights at Wyss Institute inform the company's technological framework.
- Jeff Way - Co-founder
Offers expertise in biochemistry and systems biology, drawn from his academic tenure at Harvard Medical School, enhancing the company’s innovation pipeline.
- Pam Silver - Co-founder
A noted professor at Harvard Medical School, she applies her work in synthetic biology to advance the company's academic and practical applications.
Financials and Funding
64x Bio has achieved substantial funding to support its growth, marked by a $55 million Series A financing round announced on January 19, 2022. This financing is part of a total $59.6 million raised over several rounds. The investments reflect strong confidence from the biotechnology investment community, with participation from investors like Michael Chambers and Liquid 2 Ventures.
Strategic Goals
64x Bio aims to transform the biotech and pharma industries by enhancing the production capacity for cell and gene therapies. They seek to extend the impact of their technology to broader biologics markets, including oncolytic therapies and vaccines, addressing bottlenecks in viral vector production and broadening therapeutic applications for improved patient delivery.
Contact 64x Bio through their [contact page](https://www.64xbio.com/contact) and follow updates on their [news section](https://www.64xbio.com/news).
Competitor Profiling
64x Bio operates in a competitive biotech environment, reporting an annual revenue of $2.9 million with a workforce of 38 employees.
Key Competitors
1. OrganaBio
- Foundation Year: 2018
- Headquarters: Miami, Florida
- Revenue: Approximately $5 million
- Employees: 36
- Core Focus: OrganaBio serves as a hub for tissue sourcing, clinical sample processing, and contract manufacturing, supporting regenerative medicine and cell and gene therapy advancements.
2. Cellecta, Inc.
- Foundation Year: 2006
- Headquarters: Mountain View, California
- Revenue: Approximately $6 million
- Employees: 11-50
- Specialties: Provides high-throughput genetic screening services, including CRISPR and shRNA libraries, with a strong position in the CRISPR library market.
3. Celltheon Corporation
- Foundation Year: 2012
- Headquarters: Union City, California
- Revenue: Approximately $10 million
- Core Competencies: Focuses on cell line development and process development with unique technologies like OMNICHO™, central to biopharmaceutical protein expression and manufacturing.
4. Primacyt Cell Culture Technology GmbH
- Foundation Year: 2004
- Headquarters: Schwerin, Germany
- Core Areas: Specializes in in-vitro technologies, providing cell culture systems for pharmacological and toxicological research, serving as a GLP-certified reference laboratory.
5. DiaCarta, Inc.
- Foundation Year: 2012
- Headquarters: Pleasanton, California
- Revenue: Approximately $30 million
- Specialties: Engages in personalized diagnostics and precision molecular diagnostics, focusing on ultra-sensitive cancer detection tools and next-generation sequencing.
These competitors showcase distinct capabilities and innovations that challenge 64x Bio's position in the cell line engineering and gene therapy space, with business models spanning tissue sourcing to precision diagnostics, reflecting the dynamic landscape 64x Bio navigates.
